Compare CGC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGC | RCKT |
|---|---|---|
| Founded | N/A | 1999 |
| Country | Canada | United States |
| Employees | N/A | 202 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 401.6M |
| IPO Year | 2023 | N/A |
| Metric | CGC | RCKT |
|---|---|---|
| Price | $0.94 | $3.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | ★ 4.2M | 3.1M |
| Earning Date | 05-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,759,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | $64.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $2.53 |
| 52 Week High | $2.38 | $5.45 |
| Indicator | CGC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 46.97 |
| Support Level | $0.84 | $3.36 |
| Resistance Level | $1.08 | $3.56 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 8.80 | 19.91 |
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.